1. Impact of biological therapy on spondyloarthritis

   • Nicola Maruotti
   • Francesco Paolo Cantatore

   Review Article 10 June 2014 Pages: 1021 - 1027

2. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention

   • Atefeh Jafari
   • Hossein Khalili
   • Simin Dashti-Khavidaki

   Review Article 25 June 2014 Pages: 1029 - 1040

3. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis

   • Xiaowen Hou
   • Jingpu Shi
   • Hao Sun

   Review Article 05 July 2014 Pages: 1041 - 1047

   

4. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y₁₂ inhibition: Results of the randomized DOSAPI study

   • Jean-Philippe Collet
   • Jean-Sébastien Hulot
   • for the DOSAPI investigators.

   Clinical Trial 12 July 2014 Pages: 1049 - 1057

   

5. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

   • José-Francisco Rocha
   • Amílcar Falcão
   • Patrício Soares-da-Silva

   Pharmacodynamics 14 June 2014 Pages: 1059 - 1071

   

6. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

   • Mitsushige Sugimoto
   • Naohito Shirai
   • Takahisa Furuta

   Pharmacodynamics 06 July 2014 Pages: 1073 - 1078

   

7. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

   • Ching-Soon Ng
   • Abul Hasnat
   • Ann K. Daly

   Pharmacogenetics 03 June 2014 Pages: 1079 - 1086

8. Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers

   • Yumiko Akamine
   • Masatomo Miura
   • Norio Yasui-Furukori

   Pharmacokinetics and Disposition 07 June 2014 Pages: 1087 - 1095

   

9. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins

   • Kyra J. Barnes
   • Andrew Rowland
   • John O. Miners

   Pharmacokinetics and Disposition 24 June 2014 Pages: 1097 - 1106

   

10. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone

    • Wen H. Lin
    • Hwa-Ping Feng
    • Joan R. Butterton

    Pharmacokinetics and Disposition 05 July 2014 Pages: 1107 - 1113

    

11. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions

    • Ben D. Snyder
    • Andrew Rowland
    • Matthew P. Doogue

    Pharmacokinetics and Disposition 17 July 2014 Pages: 1115 - 1122

    

12. Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database

    • François Montastruc
    • Cannelle Duguet
    • Jean-Louis Montastruc

    Pharmacoepidemiology and Prescription 14 June 2014 Pages: 1123 - 1127

13. Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures

    • Arianna Ghirardi
    • Mauro Di Bari
    • This study is on behalf of the BEST investigators

    Pharmacoepidemiology and Prescription 22 June 2014 Pages: 1129 - 1137

14. Psychotropic medication in geriatric psychiatric patients: use and unreported use in relation to serum concentrations

    • Marit Tveito
    • Jørgen G. Bramness
    • Gudrun Høiseth

    Pharmacoepidemiology and Prescription 18 July 2014 Pages: 1139 - 1145

15. Atropinic burden of prescription forms in France: a study in community pharmacies in 2013

    • François Montastruc
    • Elodie Retailleau
    • Jean-Louis Montastruc

    Letter to the Editors 12 July 2014 Pages: 1147 - 1148